Complement-Directed Therapy in Cold Agglutinin Disease

Prev
 1 / 14 
Next
Prev
 1 / 14 
Next

Learning objectives

After completing this quiz, the learner should be able to:

  • explain why CAD is best understood as a complement-driven hemolytic disorder
  • distinguish complement inhibition from clone-directed therapy by mechanism, tempo, goal, and clinical context
  • identify when complement-directed therapy is preferred
  • recognize the limits and common misapplications of complement inhibition in CAD

Why is complement-directed therapy considered the most biologically direct way to control active CAD?

a
It reduces production of pathogenic IgM
IgM production is targeted by clone-directed therapy, not complement inhibition.
b
It blocks classical pathway activation that determines disease expression
Disease expression in CAD is driven by classical complement activation leading to C3b/iC3b opsonization and hepatic clearance.
c
It prevents IgM from binding to red cells
Complement inhibition acts downstream of antibody binding.
d
It eradicates the underlying B-cell clone
Complement-directed therapy does not affect clonal persistence.

Which complement effector event is most responsible for red-cell destruction in primary CAD?

a
Membrane attack complex–mediated intravascular lysis
Intravascular hemolysis is usually limited in typical primary CAD.
b
IgM-mediated agglutination alone
IgM binding initiates disease but does not determine phenotype alone.
c
C3b/iC3b opsonization with hepatic macrophage clearance
Extravascular hemolysis via C3-opsonized red cells cleared primarily by the liver is the dominant mechanism.
d
Splenic sequestration independent of complement
Clearance is typically hepatic rather than splenic in CAD.

Why are terminal complement inhibitors (e.g., C5 blockade) generally ineffective in CAD?

a
They act too slowly to control acute hemolysis
C5 inhibitors act quickly but target the wrong step.
b
They do not prevent C3 deposition on red cells
locking C5 leaves upstream C3 opsonization intact, allowing continued extravascular hemolysis.
c
They fail to inhibit the alternative pathway
Alternative pathway inhibition is not required in CAD.
d
They worsen IgM binding to erythrocytes
Complement blockade does not affect antibody binding.

A patient with CAD presents with symptomatic anemia and rapidly worsening hemolysis. Which therapeutic goal most strongly favors complement-directed therapy?

a
Achieving durable remission
Durable remission is a goal of clone-directed therapy.
b
Eliminating the pathogenic B-cell clone
Complement inhibition does not target the clone.
c
Avoiding continuous therapy
Complement inhibition is typically continuous therapy.
d
Rapid and predictable control of hemolysis
Complement-directed therapy provides rapid, reproducible suppression of hemolysis.

Which feature best distinguishes proximal classical pathway inhibition (e.g., C1s inhibition) from broader complement blockade?

a
Broader immunosuppression
Proximal classical inhibition avoids broad immunosuppression.
b
Preservation of alternative and lectin pathways
Selective C1 inhibition preserves alternative and lectin pathway activity.
c
Delayed onset of benefit
Clinical benefit is rapid, not delayed.
d
Greater efficacy against intravascular hemolysis
Intravascular hemolysis is not the dominant mechanism in CAD.

Which is a common misapplication of complement-directed therapy in CAD?

a
Using it to rapidly stabilize active hemolysis
This is a core and appropriate indication.
b
Continuing therapy to maintain disease control
Continuous therapy is expected because antibody production persists.
c
Expecting durable remission after discontinuation
Hemolysis typically recurs when complement inhibition is stopped.
d
Selecting it in patients with contraindications to immunosuppression
Complement-directed therapy is often preferred in this setting.

Which patient is most appropriate for complement-directed therapy as initial management?

a
Transfusion-dependent anemia with active hemolysis
Active, clinically significant hemolysis is the strongest indication for complement inhibition.
b
Stable hemoglobin of 11 g/dL with minimal symptoms
Observation may be appropriate when disease impact is minimal.
c
Mild anemia with strong preference for finite therapy
Preference for finite therapy aligns more closely with clone-directed approaches.
d
Asymptomatic patient with elevated cold agglutinin titer
Antibody titers alone do not determine treatment need.

A patient with severe, rapidly progressive CAD will receive clone-directed therapy for long-term disease modification. What role can complement-directed therapy play?

a
It is contraindicated alongside clone-directed therapy
The strategies can be combined or sequenced.
b
It can provide rapid control while awaiting slower clone suppression
Complement inhibition can stabilize hemolysis while clone-directed therapy takes effect.
c
It should replace clone-directed therapy entirely
Complement inhibition does not modify disease origin.
d
It is useful only after clone-directed therapy fails
Its value is not limited to salvage settings.

Sort each item into the correct category

rapidly controls active hemolysis
benefit evolves over months
suppresses antibody production
acts at the effector phase of disease
aims for disease modification
benefit typically seen within days to weeks
Complement-directed therapy
Clone-directed therapy

Match each strategy to its dominant clinical role:

Proximal classical pathway inhibition (C1s)
Clone-directed therapy
Terminal complement inhibition (C5)
Reduction of pathogenic IgM over time
Limited role in CAD; upstream pathology persists
Rapid suppression of extravascular hemolysis
Correct! Sorry, Incorrect.

Closing Note

Complement-directed therapy in cold agglutinin disease is powerful not because it cures the disease, but because it reliably interrupts its most visible expression.

Its value lies in speed, predictability, and reversibility. It offers clinicians a way to stop active hemolysis when waiting is unsafe, without committing the patient to immunosuppression or long-term disease redesign. That strength is also its limitation: when therapy stops, hemolysis returns, because the underlying antibody biology remains.

Mastery of complement-directed therapy therefore depends less on knowing how it works than on knowing when it is needed, what problem it is meant to solve, and when it is time to reassess the broader strategy. Used thoughtfully, it is not a shortcut or a stopgap, but a deliberate tool within a larger, goal-based treatment plan.

In cold agglutinin disease, complement inhibition is not an endpoint.
It is a means of restoring stability so that judgment can operate.

Prev
 1 / 14 
Next